TriNetX will link its de-identified real-world health data—covering roughly 300 million individuals—with Regeneron’s discovery and development efforts, adding genomics and proteomics to accelerate drug targeting and therapeutic development. The access will be exclusive, secure, and licensed, positioning the collaboration as a data-aggregation play. For biotech workflows, the practical impact is faster hypothesis testing across molecular strata and more efficient cohort identification for precision development. The combination of genomic and proteomic coverage also helps sponsors build more biologically anchored models of disease progression and treatment response. The industry will watch how Regeneron uses the dataset to prioritize programs and whether similar RWE deals expand across other large platforms in 2026.